Detalhe da pesquisa
1.
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
J Gastroenterol Hepatol
; 31(10): 1757-1765, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26992248
2.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
J Hepatol
; 62(2): 294-302, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25239078
3.
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Liver Int
; 35(1): 108-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24517252
4.
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
J Infect Dis
; 209(5): 668-75, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24154738
5.
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrob Agents Chemother
; 58(2): 1136-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295986
6.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811112
7.
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 514-23, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359491
8.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Hepatology
; 58(2): 524-37, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23348636
9.
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
J Hepatol
; 55(5): 972-9, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21354234
10.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Lancet
; 376(9751): 1467-75, 2010 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20951424
11.
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
J Infect Dis
; 202(10): 1510-9, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20942646
12.
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Hepatology
; 48(2): 385-97, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18570306
13.
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
PLoS One
; 11(1): e0145409, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26752189